Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
LJtmkRWQ3WWyEGSn
